WO1984000543A1 - Single crystalline dl-cysteine and process for their preparation - Google Patents
Single crystalline dl-cysteine and process for their preparation Download PDFInfo
- Publication number
- WO1984000543A1 WO1984000543A1 PCT/JP1983/000241 JP8300241W WO8400543A1 WO 1984000543 A1 WO1984000543 A1 WO 1984000543A1 JP 8300241 W JP8300241 W JP 8300241W WO 8400543 A1 WO8400543 A1 WO 8400543A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cysteine
- strong
- hydroxide
- solvent
- water
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C319/00—Preparation of thiols, sulfides, hydropolysulfides or polysulfides
- C07C319/02—Preparation of thiols, sulfides, hydropolysulfides or polysulfides of thiols
- C07C319/12—Preparation of thiols, sulfides, hydropolysulfides or polysulfides of thiols by reactions not involving the formation of mercapto groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
- C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
- C07C323/57—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups
- C07C323/58—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups with amino groups bound to the carbon skeleton
Definitions
- the present invention relates to a single-crystal DL-cysteine and a method for producing the same. More specifically, the present invention relates to a crystalline DL-system characterized by the following X-ray diffraction spectrum and a method for producing the same.
- DL-Cysteine is a type of sulfur-containing amino acid, and is a substance that has a wide range of uses in liquids for 0 , 0- mounts, and raw materials for pharmaceuticals.
- cystine is easily oxidized by oxygen in the air into cystine.
- conventionally known free DL-cysteine is an amorphous form having no crystallinity, and thus is susceptible to oxidation during storage, and
- DL-cysteine hydrochloride monohydrate Due to the lack of stability, it is used for various purposes exclusively in the form of DL-cysteine hydrochloride monohydrate.
- DL-cysteine hydrochloride is generally used because it is generally formulated at pH 9 or higher. Neutralized with a suitable base, and used after adjusting PH. Therefore, if the preparation can be carried out using free DL-cysteine, it is economically advantageous because the amount of the base used is only sufficient for adjusting the pH.
- the hydrochloride of DL-cysteine or p-toluenesulfonate is dissolved in methanol, A method of neutralizing with a base such as triethylamine is generally used.
- the DL-cysteine obtained by this method has no crystal form and is indefinite, so it is easily oxidized at the time of storage and easily becomes cis. There was a problem of lack of stability.
- An object of the present invention is to provide a single crystalline DL-cysteine having a crystalline form and excellent storage stability, and a method for producing the same.
- a DL-cysteine having single crystallinity characterized by the above-mentioned X-ray diffraction spectrum.
- the hydrochloride or aromatic of DL-cysteine is used. Sulfonate is suspended or dissolved in a mixed solvent of water and an organic solvent selected from lower alcohols and cellosolves, and neutralized with a base to form a single crystalline DL. -A method for manufacturing the cysteine is provided.
- -Cysteine is a free DL-cysteine having a scaly or short needle-like crystal form and having good storage stability.
- the monocrystalline DL-cysteine of the present invention is a DL-cysteine having the crystallinity specified by the following X-ray diffraction spectrum. .
- Relative strength (J) indicates an arbitrarily set criterion as follows.
- the method for producing a single crystalline DL-cysteine of the present invention comprises the steps of:
- An aromatic sulfonate or hydrochloride of DL-cysteine is suspended or dissolved in a mixed solvent of water and an organic solvent selected from lower alcohols and cellulose esters to form a base. Neutralize with
- a substituted or unsubstituted benzenesulfonate is generally frequently used. More specifically, benzene snorfonate, p-toluenesulfonate, P-ethyl benzene sensolefonate, P-ethyl benzene -Black mouth Benzensulfonate, m-Xylene sulfonate, Sulfosalicylate, m-Nit mouth Benzensulfonate And a-naphthyl sulfonate or 3-naphthyl sulfonate.
- D L -cysteine hydrochloride the D L -cysteine ⁇ may be either anhydrous or monohydrate.
- the base used in the method of the present invention is a water-containing lower alcohol used as a solvent.
- Various bases can be used without any particular limitation as long as they form a salt that can be dissolved in alcohol or the like.
- a base that forms a salt that is hardly soluble in hydrated lower alcohols or the like is not preferable because it is difficult to separate the precipitated and difficult DL-cysteine.
- the base used in the method of the present invention include ethynoleamine, ethynoleamine, triethylamine, and monoethanolamine. , Triethanolamine, pyramid, etc. Or an organic base such as pyridin, or lithium hydroxide, sodium hydroxide, hydroxylated water, calcium hydroxide or barium hydroxide. Hydroxides, lithium carbonate, sodium carbonate, calcium carbonate, calcium carbonate or calcium carbonate Examples thereof include carbonates of aluminum metal or alkaline earth metal such as um, and ammonia.
- the method of the present invention is carried out in a mixed solvent of water and an organic solvent selected from lower alcohols and cellosolves.
- the organic solvent used METHANOL, et motor Roh Lumpur, n - profile Nono 0 Bruno Lumpur, Lee Seo profile Nono 0 Bruno Nore, carbon atoms and a tertiary butanoate Lumpur Water-miscible organics such as lower alcohols of 1 to 4 or cellosolves such as methylcellosolve, ethyl alcohol, etc. It is a solvent.
- these organic solvents contain water, and the degree of water content is 5% by weight or more, and the upper limit is not particularly limited. If the amount is too high, the DL-cysteine recovery rate will decrease. Therefore, the range of usually 5 to 60% by weight, preferably 10 to 50% by weight is good. If the amount of water is less than 5% by weight, the resulting free DL-cysteine has no crystalline form and is amorphous, resulting in poor storage stability.
- OMPI Usually 0.5 to 10 times, preferably 1 to 6 times, the weight of DL-cysteine aromatic sulfonate in relation to the operating surface or the recovery of DL-cysteine. It is used in the range of 1 to 20 times by weight, preferably 2 to 10 times by weight, relative to DL-cysteine hydrochloride.
- the method of the present invention comprises dissolving or suspending the aromatic sulfonate or hydrochloride of DL-cysteine in the mixed solvent.
- the base is added dropwise or blown in to neutralize, thereby precipitating free DL-cysteine.
- After neutralization if necessary, cool down and separate the suspended DL-sistine that has precipitated.
- the atmosphere during the neutralization is preferably in an inert gas atmosphere such as nitrogen or argon to prevent the deterioration of the system into cysteine. . In this way, a free-standing DL-cysteine having a scaly or short needle-like crystal form and excellent storage stability can be obtained.
- DL-Cistine's P-toluenesulfonate 29.3 ⁇ was suspended in 70 ml of methanol containing 10% by weight of water.
- Triethylamine 10.1 ⁇ was added dropwise from 0 to 5 with stirring under a nitrogen atmosphere to neutralize. After stirring at the same temperature for 1 hour, the precipitated crystals are separated, washed with methanol, and then dried under vacuum to prevent colorless flaky crystals from disturbing.
- Example 2 the force of the DL-system p-toluenesulfonate was added to the DL-system's p-toluene mouth vent. Using phosphate 31.3 and water as solvent 30 weight
- DL-Cistine hydrochloride monohydrate 52.7 was added to and dissolved in methanol 240 containing 10% by weight of water. O 20 to 25 with stirring under a nitrogen atmosphere Then, neutralization was carried out by dropping '3 0.3 f triethylamine in about 20 minutes. After stirring at the same temperature for 1 hour, the precipitated crystals are separated, washed with methanol and dried in vacuo to give a free DL-system of 35.1 colorless short needles. O Purity analysis by high performance liquid chromatography showed that the product was 100% pure and free of cistern o
- the procedure was the same as in column 4 except that the amount of triethylamine was changed to pyrimine 23.7 and the amount of colorless scale of 32.5 ⁇ was measured.
- a free DL-cysteine of crystalline crystals was obtained.
- the purity of this product was 100%, and the X-ray diffraction pattern of the crystal was almost the same as that of Example 4.
- Example 4 In the same manner as in Example 4 except that the triethylamine in Example 4 is replaced with 28% ammonia water 18.5 f.
- DL-cysteine hydrochloride monohydrate 52.7 is added and suspended in methanol 20% containing 20% by weight of water. 20 to 25X with stirring under a nitrogen atmosphere : Lithium hydroxide 12.6 ⁇ was gradually neutralized by applying force D, and then stirred at the same temperature for 1 hour. Precipitated crystals are separately washed with methanol, and then dried under vacuum to make colorless flaky crystals difficult
- Example 1 The free cone DL-cysteine obtained in Example 1 and Comparative Example was placed in a glass crystallizing dish and allowed to stand in a normal room to examine the storage stability. O The results are shown in Table-1.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicinal Preparation (AREA)
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB08406435A GB2137617B (en) | 1982-07-29 | 1983-07-26 | Single crystalline dl-cysteine and process for their preparation |
NL8320217A NL8320217A (nl) | 1982-07-29 | 1983-07-26 | Eenkristal d1-cysteine en werkwijze voor het bereiden daarvan. |
DE19833390129 DE3390129C2 (de) | 1982-07-29 | 1983-07-26 | Verfahren zur Herstellung von kristallinem Dl-Cystein |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP57131095A JPS5921662A (ja) | 1982-07-29 | 1982-07-29 | 結晶性dl―システィン |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1984000543A1 true WO1984000543A1 (en) | 1984-02-16 |
Family
ID=15049856
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP1983/000241 WO1984000543A1 (en) | 1982-07-29 | 1983-07-26 | Single crystalline dl-cysteine and process for their preparation |
Country Status (9)
Country | Link |
---|---|
EP (1) | EP0115539B1 (ja) |
JP (1) | JPS5921662A (ja) |
KR (1) | KR870000546B1 (ja) |
AU (1) | AU551788B2 (ja) |
CH (1) | CH660185A5 (ja) |
DE (1) | DE3390129C2 (ja) |
GB (1) | GB2137617B (ja) |
NL (1) | NL8320217A (ja) |
WO (1) | WO1984000543A1 (ja) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4849210A (en) * | 1985-05-08 | 1989-07-18 | Molecular Biosystems, Inc. | Magnetic resonance imaging of liver and spleen with superparamagnetic contrast agents |
JP3053767B2 (ja) * | 1996-05-16 | 2000-06-19 | 富士工業株式会社 | 釣竿用リールシート |
-
1982
- 1982-07-29 JP JP57131095A patent/JPS5921662A/ja active Granted
-
1983
- 1983-07-26 DE DE19833390129 patent/DE3390129C2/de not_active Expired
- 1983-07-26 CH CH1642/84A patent/CH660185A5/de not_active IP Right Cessation
- 1983-07-26 AU AU17758/83A patent/AU551788B2/en not_active Ceased
- 1983-07-26 NL NL8320217A patent/NL8320217A/nl not_active Application Discontinuation
- 1983-07-26 EP EP83902295A patent/EP0115539B1/en not_active Expired
- 1983-07-26 GB GB08406435A patent/GB2137617B/en not_active Expired
- 1983-07-26 WO PCT/JP1983/000241 patent/WO1984000543A1/ja active IP Right Grant
- 1983-07-29 KR KR1019830003553A patent/KR870000546B1/ko not_active IP Right Cessation
Non-Patent Citations (2)
Title |
---|
No relevant documents have been disclosed * |
See also references of EP0115539A4 * |
Also Published As
Publication number | Publication date |
---|---|
NL8320217A (nl) | 1984-06-01 |
JPS649311B2 (ja) | 1989-02-16 |
GB2137617A (en) | 1984-10-10 |
EP0115539A4 (en) | 1984-11-21 |
CH660185A5 (de) | 1987-03-31 |
JPS5921662A (ja) | 1984-02-03 |
DE3390129C2 (de) | 1987-09-10 |
KR870000546B1 (ko) | 1987-03-18 |
GB2137617B (en) | 1986-04-16 |
GB8406435D0 (en) | 1984-04-18 |
AU1775883A (en) | 1984-02-23 |
EP0115539A1 (en) | 1984-08-15 |
KR840005714A (ko) | 1984-11-15 |
DE3390129T1 (de) | 1984-07-12 |
EP0115539B1 (en) | 1986-10-29 |
AU551788B2 (en) | 1986-05-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0339882A1 (en) | Process for the production of lactide | |
CA1124735A (en) | Preparation of 2-aryl-propionic acids by direct coupling utilizing a mixed magnesium halide complex | |
WO1984000543A1 (en) | Single crystalline dl-cysteine and process for their preparation | |
EP3527556A1 (en) | Method for preparing deuterated imidazole diketone compound | |
JPS648616B2 (ja) | ||
RU2561125C2 (ru) | Способ получения гормонов щитовидной железы и их солей | |
NO752972L (ja) | ||
JPH0615514B2 (ja) | 飽和脂肪族α,ω−ジアミノモノカルボン酸のN,ωトリフルオロアセチル化方法 | |
JP2501852B2 (ja) | S−カルボキシメチル−l−システインの製造法 | |
EP0274876B1 (en) | Process for preparing bis(ethoxythiocarbonyl)sulfide | |
EP0157151B1 (en) | New process for preparing cis-3,3,5-trimethylcyclohexyl-d,l-alpha-(3-pyridinecarboxy)-phenylacetate | |
US4550193A (en) | Process for the preparation of 2,3-dimercaptosuccinic acid and its lower alkyl esters | |
KR940002711B1 (ko) | 2-n-옥틸-4-이소티아졸린-3-온의 제조방법 | |
SU514831A1 (ru) | Способ получени производных оксазолидино-(3,2- ) пиридо (2,3- ) или оксазолидино (3,2- ) пиримидо (4,5- ) (1,4)тиазина | |
JPS6023362A (ja) | 結晶性dl―システィンの製造方法 | |
JP2543704B2 (ja) | 有機ゲルマニウム化合物の製造方法 | |
JPS61225170A (ja) | ジスルフイド型ビタミンb↓1またはその誘導体の製法 | |
JPS6013018B2 (ja) | 新規な結晶構造を有するテトラキス〔3−(3,5−ジ−t−ブチル−4−ヒドロキシフエニル)プロピオニルオキシメチル〕メタン | |
KR0173315B1 (ko) | 6-아실-7-데아세틸포르스콜린 유도체의 제조방법 | |
JPH0513938B2 (ja) | ||
CS240017B1 (cs) | Kyseliny 4-akryloyloxy- a 4-methakryloyloxy-fenyloctová, a Jejích alkylestery a způsob jejich výroby | |
JPS5927883A (ja) | 4−オキソ−4,5,6,7−テトラヒドロベンゾフランの製造方法 | |
GB2129792A (en) | Sulpiride derived compound | |
JPS63166859A (ja) | 2−メルカプトアルキルカルボン酸アリ−ルエステル類およびその製造法 | |
JPH04112880A (ja) | 4,4―ジアルキル置換チアゾリジンチオンの製造方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Designated state(s): AU CH DE GB NL US |
|
AL | Designated countries for regional patents |
Designated state(s): FR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1983902295 Country of ref document: EP |
|
RET | De translation (de og part 6b) |
Ref document number: 3390129 Country of ref document: DE Date of ref document: 19840712 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 3390129 Country of ref document: DE |
|
WWP | Wipo information: published in national office |
Ref document number: 1983902295 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 1983902295 Country of ref document: EP |